pADH59
pADH59
规格:
货期:
编号:TS163389
品牌:Testobio
| 产品名称： | pADH59 |
|---|---|
| 商品货号： | TS163389 |
| Designations： | pADH59 |
| Species： | Homo sapiens, human |
| Depositors： | Amgen, Inc., DL Hare, Amgen, Inc. |
| Applications： | produces protein epidermal growth factor urogastrone |
| Vector： | DESCRIPTION OF VECTOR COMPONENT: Name of vector: unknown Intact vector size: Type of vector: plasmid Vector end: EcoRI Vector end: SalI Cloning sites: Polylinker sites: Host range: Escherichia coli Features (with orientation and position when available): marker(s): ampR Cross references: |
| Insert： | DNA: Synthetic DESCRIPTION OF INSERT COMPONENT: Genome: human Gene symbol: EGF Genomic copy number: unique Gene name: epidermal growth factor Contains complete coding sequence?: U Chromosome: 4; Localization: 4 q25 Type of DNA: synthetic Insert 5 end: EcoRI Insert 3 end: SalI Insert size (kb): 1.75 Cross references: Insert lengths(kb): 1.75 Gene product: epidermal growth factor(urogastrone) EGF Alleles: A1, B1, B2, A2 Target Gene: epidermal growth factor |
| Insert Size (kb)： | 1.75 |
| Media： | ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Shipping Information： | Distributed: freeze-dried |
| Comments： | Restriction digests of the clone give the following sizes (kb): EcoRI/SalI--3.3, 1.75; EcoRI--5.1; SalI--5.1; BamHI--4.9, 0.2. Runaway vector contains a temperature-sensitive mutation in the copy-control gene. Maintained at a low copy number below 34C; replication increases 50-fold at temperatures greater than 34C. Growth at 37C is lethal. The 1.75 kb EcoRI/SalI fragment contains a trp promoter/regulator and the EGF/urogastrone coding region. The complete coding sequence of the mature peptide, plus a "pro" sequence of 8 aa, is contained in a 0.2 kb XbaI/SalI fragment. Directs the synthesis of a peptide of 61 aa, including an 8-residue "leader" sequence. Expresses the urogastrone analog product on the order of 50 mg per O. D. liter as determined by SDS-PAGE. The microbially expressed product is biologically active. Constructed from oligonucleotides selected to reflect the codon usage of Escherichia coli. Contains a HinfI site interrupting Asp3, an SphI site interrupting Cys31, and an NruI site after Tyr44. |
| References： | Banks AR, Hare DL. Manufacture and expression of genes for urogastrone and polypeptide analogs thereof. US Patent 4,764,593 dated Aug 16 1988 |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
首页 >
产品中心
>
微生物培养
>
菌株
>
null
>
pADH59
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | pADH59 |
|---|---|
| 商品货号： | TS163389 |
| Designations： | pADH59 |
| Species： | Homo sapiens, human |
| Depositors： | Amgen, Inc., DL Hare, Amgen, Inc. |
| Applications： | produces protein epidermal growth factor urogastrone |
| Vector： | DESCRIPTION OF VECTOR COMPONENT: Name of vector: unknown Intact vector size: Type of vector: plasmid Vector end: EcoRI Vector end: SalI Cloning sites: Polylinker sites: Host range: Escherichia coli Features (with orientation and position when available): marker(s): ampR Cross references: |
| Insert： | DNA: Synthetic DESCRIPTION OF INSERT COMPONENT: Genome: human Gene symbol: EGF Genomic copy number: unique Gene name: epidermal growth factor Contains complete coding sequence?: U Chromosome: 4; Localization: 4 q25 Type of DNA: synthetic Insert 5 end: EcoRI Insert 3 end: SalI Insert size (kb): 1.75 Cross references: Insert lengths(kb): 1.75 Gene product: epidermal growth factor(urogastrone) EGF Alleles: A1, B1, B2, A2 Target Gene: epidermal growth factor |
| Insert Size (kb)： | 1.75 |
| Media： | ATCC® Medium 1227: LB Medium (ATCC medium 1065) with 50 mcg/ml ampicillin |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Shipping Information： | Distributed: freeze-dried |
| Comments： | Restriction digests of the clone give the following sizes (kb): EcoRI/SalI--3.3, 1.75; EcoRI--5.1; SalI--5.1; BamHI--4.9, 0.2. Runaway vector contains a temperature-sensitive mutation in the copy-control gene. Maintained at a low copy number below 34C; replication increases 50-fold at temperatures greater than 34C. Growth at 37C is lethal. The 1.75 kb EcoRI/SalI fragment contains a trp promoter/regulator and the EGF/urogastrone coding region. The complete coding sequence of the mature peptide, plus a "pro" sequence of 8 aa, is contained in a 0.2 kb XbaI/SalI fragment. Directs the synthesis of a peptide of 61 aa, including an 8-residue "leader" sequence. Expresses the urogastrone analog product on the order of 50 mg per O. D. liter as determined by SDS-PAGE. The microbially expressed product is biologically active. Constructed from oligonucleotides selected to reflect the codon usage of Escherichia coli. Contains a HinfI site interrupting Asp3, an SphI site interrupting Cys31, and an NruI site after Tyr44. |
| References： | Banks AR, Hare DL. Manufacture and expression of genes for urogastrone and polypeptide analogs thereof. US Patent 4,764,593 dated Aug 16 1988 |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
